Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material.
Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992.
Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.
From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet
Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice.
Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.
Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.
Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.
Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material.
We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.
Find out about our current vacancies at Berlin-Chemie directly on our career portal.
Within the Menarini Group, Berlin-Chemie is the regional headquarters for the CEE and CIS region and is responsible for more than 30 countries and their local subsidiaries.
As a reliable partner in the healthcare sector, we want to use our products and expertise to help solve the complex challenges in the healthcare sector in these regions. To this end, Berlin-Chemie has established strong partnerships at all levels in many countries. We support doctors and patients with high-quality medical products and technologies to improve the quality of life.
BERLIN-CHEMIE AG
Glienicker Weg 125
12489 Berlin, Deutschland
E-mail: info@berlin-chemie.de
Phone: +49 (0)30 6707-0
Fax: +49 (0)30 6707-2120
2010 - 09 - 10
The Menarini Group, in its continuous effort to value the health and well-being of women, has launched a new line, AGENA, in support of women during the more delicate moments of their life.
AGENA LUNARIS is a dietary supplement that, thanks to its effective components, helps combat pre-menstrual symptoms experienced by most women such as water retention, headache, nervousness, irritability, breast tenderness and cramps. Pre-menstrual syndrome affects about 40% of women and is often not given the attention it deserves. The women who suffer from it know how limiting the symptoms can be and now with this completely natural supplement they have a valuable aid.
AGENA MAMMA is for expectant and breast-feeding mothers. It helps reduce the risk of fetal and infant illness deriving from the deficiency of important elements by providing essential substances to the fetus and infant before, during and after pregnancy, including the entire nursing period.
The AGENA line has been studied and developed in collaboration with the scientific advisory panel SIFIOG (Italian Society of Nutrition and Phytotherapy in Obstetrics and Gynecology). "It is a great pleasure to work with Menarini for the development of these products given their effectiveness and innovation. On behalf of the scientific committee which I represent, I have given my approval following thorough assessment of the formulation’s quality, the manufacturing and control processes and of the products’ scientific evidence, which are the same criteria used in evaluating pharmaceutical products," commented Prof. Vittorio Unfer, President of SIFIOG.